Conflicting signals from drug regulator, COVID-19 national task force

There have been at least three instances where the drug regulator has approved a drug or vaccine but the COVID-19 National Task Force has taken a diametrically opposite stand and not included the drug/vaccine in the national treatment protocol. But the task force was quick to accept the and include the approval given to repurposed … Continue reading Conflicting signals from drug regulator, COVID-19 national task force

Two COVID-19 antivirals get FDA nod for emergency use

Paxlovid is not recommended for patients with severe kidney or liver disease, and if given to people with uncontrolled or undiagnosed HIV infection may result in HIV drug resistance. Molnupiravir is not recommended for use during pregnancy as the drug may harm the foetus. If full vaccination with any of the COVID-19 vaccines greatly reduces … Continue reading Two COVID-19 antivirals get FDA nod for emergency use

Pfizer’s antiviral Paxlovid is a major advancement potentially for all coronaviruses, says Gagandeep Kang

Gagandeep Kang Besides 89% efficacy in preventing death and hospitalisation in specific groups that have high risk of progressing to severe disease when treatment is initiated within five days of symptoms showing up, Pfizer's antiviral against SARS-CoV-2 virus has been found to limit damage to lung tissue in human cells and mouse models of SARS-CoV-2. … Continue reading Pfizer’s antiviral Paxlovid is a major advancement potentially for all coronaviruses, says Gagandeep Kang

SARS-CoV-2 virus less likely to develop resistance to molnupiravir: Gagandeep Kang

Preliminary data, which is yet to be peer-reviewed, shows molnupiravir can reduce risk of hospitalisation or death by 50% in non-hospitalised adult patients with mild-to-moderate COVID-19 disease. The trial included only those older than 60 years and have at least one comorbidity. On October 11, just 10 days after Merck announced via a press release … Continue reading SARS-CoV-2 virus less likely to develop resistance to molnupiravir: Gagandeep Kang